

## Tozinameran

S

### Exacerbation of subacute cutaneous lupus erythematosus: case report

A 73-year-old woman exhibited an exacerbation of subacute cutaneous lupus erythematosus (SCLE) following vaccination with tozinameran for COVID-19 infection.

The woman was diagnosed with SCLE in 2005 and had typical skin lesions, which partly resulted in hypopigmentation. Her history was significant for recurrent Raynaud's syndrome with digital ulcerations, joint pain and diffuse hair loss. She was previously treated with hydroxychloroquine and unspecified corticosteroids and she had been in full remission from January 2020 without any treatment. For immunization against COVID-19, she received first dose of tozinameran [BNT162b2 mRNA] vaccine on 27 March 2021 [*dosage and route not stated*]. However, after 10 days, she developed disseminated burning erythematous patches and fatigue. An exacerbation of SCLE was noted.

The woman then treated with prednisolone, which failed to achieve control, Therefore, prednisolone was increased over 3 weeks in combination with mometasone, which lead to amelioration.

After 6 weeks, the woman received the second dose of tozinameran and did not experience any adverse reaction. It was postulated that the SCLE exacerbation was secondary to tozinameran vaccine.

Niebel D, et al. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine. *Dermatologic Therapy* 34: No. 4, Jul-Aug 2021. Available from: URL: <http://doi.org/10.1111/dth.15017>

803594336